Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

NCT06978725 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.

NCT NCT06978725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06978725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis
Lead sponsor
Priovant Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 9, 2025
Completion date
December 31, 2029
Enrollment
168 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous sarcoidosis